Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

AstraZeneca will present the latest clinical and real-world ... chronic bronchitis and smoking status. • Tozorakimab: Demonstrating potential benefits of tozorakimab to reduce excess inflammation in ...

WILMINGTON, Del., May 13, 2025--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

inhibitor tozorakimab (AstraZeneca). Additionally, the CD40/CD40L axis may introduce therapeutic alternatives for systemic diseases, including dazodalibep (Amgen) for Sjögren’s syndrome and ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up to $1 billion, expanding its treatments for cancer. EsoBiotec's ...

Tozorakimab received FDA Fast Track Designation ... Alexion and Chief Strategy Officer, AstraZeneca Thank you, Sharon, and next slide, please. The rare disease delivered total revenue of $8.8 ...

AstraZeneca (NASDAQ:AZN ... including camizestrant, baxdrostat, tozorakimab, and eneboparatide. At the same time, when forecasting the growth rates of the company's revenue and operating income ...